Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/173730
Title: Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice
Author: Cano Fernández, Amanda
Ettcheto Arriola, Miren
Espina García, Marta
Auladell i Costa, M. Carme
Folch López, Jaume
Kühne, Britta A.
Barenys Espadaler, Marta
Sánchez-López, E. (Elena)
Souto, Eliana B.
García López, María Luisa
Turowski, Patrick
Camins Espuny, Antoni
Keywords: Nanopartícules
Desenvolupament de medicaments
Malalties neurodegeneratives
Nanoparticles
Drug development
Neurodegenerative Diseases
Issue Date: 7-Jan-2021
Publisher: Future Medicine
Abstract: Huntington's disease (HD) is a debilitating neurodegenerative disease that affects around 5-10/100,000 individuals in developed countries. It is caused by genetic alterations in the huntingtin (htt) gene. Efforts are being made to find treatments which will correct the genetic alterations or their pathophysiological consequences associated with HD,3 however none of these options are yet available to patients. Thus, therapies that address and ameliorate the symptomatology of HD, which include motor dysfunction and a wide range of behavioural disturbances, are also needed. Epigallocatechin-3-gallate (EGCG) is a powerful compound extracted from the green tea plant that may possess beneficial effects for HD patients, but whose therapeutic success is limited because of its chemical instability. Here, we show that protective encapsulation of EGCG rendered it much more efficient in attenuating motor deficits and depression-like behaviour in a mice model of HD-like neurodegeneration. Importantly, behavioural improvement was also associated with a reduction of neuronal damage. These results, together with our previous findings using nanoparticle-encapsulated EGCG in mouse models of Alzheimer's disease and epilepsy, highlight their potential effectiveness for symptomatic treatment of neurodegenerative diseases.
Note: Versió postprint del document publicat a: https://doi.org/10.2217/nnm-2020-0239
It is part of: Nanomedicine, 2021, vol. 16, num. 1, p. 19-35
URI: http://hdl.handle.net/2445/173730
Related resource: https://doi.org/10.2217/nnm-2020-0239
ISSN: 1743-5889
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
706489.pdf1.58 MBAdobe PDFView/Open    Request a copy


Embargat   Document embargat fins el 7-1-2022


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.